Literature DB >> 26603728

The aged gut in inflammatory bowel diseases.

M Ardesia1, V Villanacci, W Fries.   

Abstract

Senescence is accompanied by various anatomical and functional alterations starting from mastication and deglutition and consequent modifications of nutrition. In addition, the widespread use of proton pump inhibitors and non-steroidal anti-inflammatory drugs in aged subjects weakens the gastric barrier, thus contributing to easier entry of microbes into the gastrointestinal tract. The microbiota of the elderly is less stable than that of younger adults, therefore, gut dysbiosis is more frequent. Dysbiosis represents a key factor for infections, e.g. Clostridium difficile, especially after antibiotic treatment, but also represents an important step for the development of inflammatory bowel diseases (IBD). IBD onset in the elderly needs careful evaluation in order to distinguish this entity from other pathologies that may affect the gut in senescence. Colitis associated with diverticula, drug-induced, ischemic, and microscopic colitides are among the possible diseases and, therefore, a careful macroscopic and histologic evaluation is mandatory. Finally, late onset IBD represents an important challenge for physicians since it occurs in subjects with frequent comorbidities and relative concomitant treatments. Although there is some evidence that disease course of elderly-onset IBD follows a milder course, overall morbidity, hospitalization rates and even mortality, the latter mostly due to comorbidities, are increased, especially in emergency settings.

Entities:  

Mesh:

Year:  2015        PMID: 26603728

Source DB:  PubMed          Journal:  Minerva Gastroenterol Dietol        ISSN: 1121-421X


  1 in total

1.  Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.

Authors:  Angela C Baird; Dominic Mallon; Graham Radford-Smith; Julien Boyer; Thierry Piche; Susan L Prescott; Ian C Lawrance; Meri K Tulic
Journal:  World J Gastroenterol       Date:  2016-11-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.